key: cord-0863870-1jrupz23 authors: Sankhe, Ajay Prabhakar; Memane, Nanasaheb Somnath; Gawali, Vijaykumar P; Memane, Sonal Nanasaheb; Ramakrishnan, Ganesh; Kundu, Tapanendu; Bagul, Mayur Nimba; Kumar, Ashotosh; Bansal, Vikram; Tiwari, Rashmi title: A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India. date: 2022-03-25 journal: Complement Ther Med DOI: 10.1016/j.ctim.2022.102824 sha: 2782a42b773eb91a305f4d7583f4ac022b82ca2a doc_id: 863870 cord_uid: 1jrupz23 INTRODUCTION: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven antiviral, detoxifying, immune-modulating, and bio-enhancing properties. The present study was carried out to evaluate the therapeutic effect and safety of Ayurcov in patients with various severity states of COVID-19 infections. METHODS: A randomized, single blinded, controlled trial was carried out in adults diagnosed with mild-to-moderate, and severe COVID-19 infections confirmed by real time reverse transcriptase polymerase chain reaction (rRTPCR) test. The interventional group received three doses of ‘Ayurcov’. It is constituted of Haridra Churna (Curcuma Longa), Go ark (Bos Indicus Distilled Urine), Sphatika (Alum), Sita (Rock Candy), Godugdham (Bos Indicus Milk) milk, Goghritam (Bos Indicus ghee) on Day 1, as an adjuvant to the standard of care, and the control group received only the standard of care. Key outcomes included: proportion of patients and time taken for symptom resolution, reduction in the rRT-PCR Ct values, safety, and functional status until 42 days after discharge. RESULTS: Ninety patients with mild-to-moderate and 30 patients with severe COVID-19 disease were recruited. It was observed that significantly more proportions of patients receiving Ayurcov had symptom relief much earlier than control group. Additionally, the interventional group showed significantly lower rRT-PCR Ct values. However, a shorter time of resolution of symptoms was observed with the interventional group in the mild to moderate category but not with those having severe symptoms. Similarly, a significantly better functional status was observed with interventional group on days 7 and 28 after discharge. Ayurcov was not observed with higher risks of any adverse/serious adverse events. CONCLUSIONS: Ayurcov as adjuvant with standard of care was associated with significantly earlier resolution of COVID-19 related symptoms than standard of care alone. The unprecedented COVID-19 pandemic shook the world with a mortality of 3.42 million out of the total infected cases of 165 million as of May 20, 2021. Considering the limited therapeutic options, investigators from across the globe are also exploring the benefits of various complementary and alternative medicines for the prevention and treatment of COVID-19 infections. Traditional Chinese Medicine (TCM) has been used in China to contain COVID-19 [1] . Ayurveda is a holistic system of medicine with roots from India and is one of the oldest indigenous systems of medicine with unbroken clinical practice dating back to thousands of years [2] . The Ayurvedic basis of any disease is an imbalance between three doshas (vata, pitta and kapha), one, two or three simultaneously. According to Acharya Charak , Nija hetu (Endogenous causes) directly leads to dosha imbalance but Agantuj hetu (Exogenous causes), ultimately after a while leads to dosha imbalance as Sannipatik Doshadushti [3] . The Covid 19 is caused by an exogenous cause as virus ultimately affects All three doshas imbalance inside [4] . Doshas represent the functional classification adopted in Ayurveda to understand the complex human system and manage health and diseases [5, 6] . Ayurcov is constituted of Haridra Churna (Curcuma Longa) [7] , Go ark (Bos Indicus Distilled urine) [8, 9] , Sphatika (Pottasium Alum) [10] , Sita (Rock Candy) [10] , Godugdham (Bos Indicus Milk) [11] , Goghritam (Bos Indicus ghee) [11, 12] . Although antiviral medicines are required for treating covid-19 , as per Rasayan chikitsa (a specialty of Ayurveda, stating about rejuvenation therapy) host immunity J o u r n a l P r e -p r o o f Page 5 of 33 plays a vital role for prevention of cytokine storm and quick tissue regeneration and retard aging [13] . Bos Indicus ghee (BIG) has been shown to possess anti-toxic, improves digestion, antipyretic, endurance enhancement, and immune boosting properties [14] . Bos Indicus Milk (BIM), promotes tissue repair and boosts immunity [15] . Bos Indicus distilled urine (BIDU) possesses anti-toxic properties, ameliorates cough, taste, and enhances the endurance [16] . BIDU was found to enhance Blymphocyte and T-lymphocyte blastogenesis as well as IgG, IgA, and IgM antibody titres [17] . US Patents (No. 6,896,907 and 6,410,059) for BIDU have also mentioned that it possesses bioenhancer, antibiotic, antifungal, and anticancer properties [18] . Pottasium Alum (PA) is a wound healer and possesses a local pungent action on the throat with anti-microbial property [19] . PA is known to induce an innate immune response through macrophage and mast cell sensors [20] . It is widely tested as the safest and most efficacious adjuvant component, inducing high levels of neutralizing antibodies, which are increasingly recognized as the cornerstone of the protection afforded by COVID-19 vaccines [21] . It is known to act as an antiseptic, as an antimicrobial and as a cleanser -in the throat and respiratory tract. Rock Candy (RC) reduces throat dryness and targets in treating all the three doshas [22] . Given these properties, it is imperative that the combination of above constituents is likely to improve the symptoms and signs associated with COVID-19 infections. Hence, we envisaged the present study to investigate the efficacy and safety of "Ayurcov" in patients with varied severity of COVID-19 illnesses. This study was carried out after obtaining approval from the Institutional Ethics Committee that is approved by Ministry of Health, Government of India (EC/NEW/INST/2019/245). The study was carried out between June and Nov 2020. This study was a single centre, assessor blinded, randomized, controlled trial. Services of the Government of India [22] . Patients with uncomplicated upper respiratory tract infection, with mild symptoms such as fever, cough, sore throat, nasal congestion, malaise, and headache were classified as "mild COVID-19 disease". Symptoms suggestive of pneumonia without any sign of severe disease were considered "moderate" and those experiencing any of these symptomsrespiratory frequency ≥ 30/min, blood oxygen saturation (SpO2) ≤ 90%, PaO2/FiO2 ratio < 300, or severe pneumonia were categorized as "severe COVID-19" disease. During the initial (baseline) visit, patients presenting with symptoms/signs suggestive of COVID-19 disease were confirmed with rRTPCR tests. Participants were admitted in the hospital and were evaluated on days 1, 3, from day 4 until discharge, and days 7, 28, and 42 after discharge from the hospital. The details of the assessments are listed in Table 1 . rRTPCR tests for each study participant were carried out on days 1 and 3. The eligible participants were randomized to either standard of care arm (control) or adjuvant intervention (Ayurcov) with standard of care. The standard of care consisted of the following: (i) Mild COVID-19 disease: Symptomatic treatment such as antipyretic (Paracetamol 500 mg orally every 6 hours) for fever and pain, and adequate nutrition and rehydration. Hydroxychloroquine (HCQ) at 400 mg twice daily on the first day and 200 mg twice daily for four more days orally was administered for patients with mild disease with one or more of the following risk factors for severe disease: age > 60 years, systemic hypertension, diabetes mellitus, chronic lung / kidney / liver disease, cerebrovascular disease, and obesity. Electrocardiogram (ECG) was assessed before deciding to administer HCQ. The interventional arm consisted of the following: (i) Ayurcov medication is a single day regimen, consisting of oral medication three times a day and two times gargles as detailed below. First gargle one hour prior to lunch around 12.00 noon and the second gargle (ii) The above-mentioned intervention was administered along with standard of care to all the patients. Haridra Churna: Good manufacturing practices were adhered to as specified in the Indian Food and Drug Administration Act. Haridra was checked for adulteration or contamination, following which it was grinded to a fine powder. Then, it is sieved under 60 mesh nylon cloth for uniformity and the powder was collected and checked for the basic characteristics as colour, taste, and pH. RC: An initial inspection was carried out for adulteration and contamination. Then, the suspended particles were grinded to a fine powder. After sieving the powder with 60 mesh nylon cloth for uniformity, basic characteristics such as colour, taste, and pH were checked. Primary endpoint: Proportion of patients with clinical recovery from COVID-19 related presenting symptoms. Secondary endpoints: 1. Mild to Moderate COVID-19 disease: (i) rRTPCR values on days 1 and 3, and proportion of patients with rRTPCR negative status on day 3. (ii) Time of resolution of presenting symptoms. (iii) Proportion of patients requiring intensive care unit (ICU) admission. (iv) Duration of hospitalization. (v) Functional status at the time of discharge, at days 7, 28, and 42. (vi) Incidence of adverse events. (iv) Duration of hospitalization. (v) Functional status at the time of discharge, at days 7, 28, and 42. (vi) Incidence of adverse events. Serious adverse events (SAE) were defined as per the New Drug Clinical Trials -2019 guidelines (India) and ICMR 2017 guidelines. The study participants were discharged following complete recovery. In addition, the quality of life in terms of a validated functional status scale (Electronic Supplementary Table 1 ) on days 7, 28, and 42 after discharge was evaluated. Simple unrestricted randomization technique was used, and the randomization list was generated using computer-generated (SAS) program. Treatment allocation was concealed using sequentially numbered, opaque, sealed envelopes. The assessors of the clinical response (and adverse events) as well as the investigators involved in statistical analyses were blinded to the treatment arms. The pilot study with the same hypothesis revealed a difference in the proportions of the primary endpoint to be around 9%. At a precision of 5%, with a significance level of 5%, using the formula, , and 5% drop-out rate, the sample size for each arm was estimated to be 120. Intention to-treat (ITT) analysis was carried out for all the statistical tests. interventional arms) in the 'severe group'. Figure 1 depicts the study flow diagram. In the mild to moderate group of patients, mean (SD) age was 50.92 (14.99) years and 51.29 (15.27) years in the control and intervention arms, respectively; in the severe group, 55.93 (11.48) and 56.75 (9.71) years, respectively. The other demographic characteristics are listed in Table 2 . In the mild to moderate group, 43/45 cases and 44/45 were considered for ITT analysis in the control and interventional arms respectively, because two patients in the control and one patient in the intervention arms, respectively denied the follow-up rRTPCR tests. In the severe group, 12/15 and 13/15 cases were considered for ITT analysis in the control and interventional arms, respectively. In the severe group, three patients died in the control arm and hence could not be considered for rRTPCR analysis. In the severe group (in the intervention arm), one patient withdrew consent while another patient refused the rRTPCR test and so were excluded from the analysis. Numbers of patients presenting with each of the COVID-19 symptoms at baseline, and on days 3, 5, and at the time of discharge are listed in Table 3 . Significantly more proportions of patients with mild to moderate disease showed symptom resolution on days 3 and 5 compared with interventional arm compared to control group. No significant differences were observed in patients with severe disease. Three (20%) in the control group required mechanical ventilation but none in the interventional group (p=0.1). Page 14 of 33 Ct-based precision@k values for both the groups on days 1 and 3 are depicted in Significantly In the severe category, we did not observe any significant difference between the number of patients requiring admission in ICU with the interventional compared to control group [1 (2.2%), 3 (6.7%); p = 0.6]. Adverse event and serious adverse events: Table 4 shows the comparison of adverse events between the control and the intervention arms and no significant differences were observed between the groups. No serious adverse events other than three deaths in the control arm were observed. Ayurveda interventions for prophylaxis, prevention and treatment of mild-moderate and severe cases of COVID-19 were pragmatically proposed as early as in April 2020 and was much appreciated by the global community working in the area of COVID-19 (COVID-19 pandemic [24] Further to this, number of case reports have been published endorsing the strength of [27, 28, 29] Despite the approval of remdesivir and potential claims of other anti-viral drugs in addressing the issues of hyper-inflammation of lungs, lymphocytopenia, and cytokine storms, high-quality evidence is lacking [30, 31] . Given this state, evidence backing up the therapeutic efficacy and safety for drugs belonging to CAM is the need of the hour. We could demonstrate one of such CAM formulation, Ayurcov, in the present study. In addition to clinical improvement in terms of symptom resolution, we also observed that rRTPCR Ct values significantly lowered with the Ayurcov. A strong relationship between rRTPCR Ct values and disease severity was observed in other studies [31, 32] . We did not observe any difference in the rRTPCR Ct values between day 3 and baseline amongst those with severe disease. One The ingredients used in Ayurcov are easily available in almost any region of the world. Although we did not estimate the cost-effectiveness, it is imperative that in resource-limited countries that are severely constrained for affording remdesivir, the only approved treatment for COVID-19, Ayurcov shall be a possible alternative. We did not observe any increased incidence of adverse events with Ayurcov even in J o u r n a l P r e -p r o o f The spread of doshas if targeted at early stage by Doshapachan with Ashukari qualities, has immense potential to halt the progress of the disease leading to prevention of Dhatupaak (Tissue involvement). In view of above mechanism of action and rational , study medicine The strength of the present study is the RCT design with assessors blinded, thus the observed results are reasonably robust. However, the study is limited in not evaluating the levels of various inflammatory and anti-inflammatory markers such as interleukins, and ferritin. Significantly to the control group in the mild to moderate group, indicating rapid reduction of virulence in the interventional group in just 2 days of evaluation. However no significant differences were observed in patients with severe disease , another clinical trial with increased frequency of study medicine doses is required to be carried out to further explore its efficacy in severe disease . Ayurcov was not worsening of pre-existing symptoms and were followed until complete resolution of symptoms. 7. Post discharge follow-up was done at day 7, 28, and 42 using validated functional assessment scale. Table 2 . Demographic characteristics of the study participants (N=120) rRTPCR -real time reverse transcriptase polymerase chain reaction; αrepresented in mean (SD); βrepresented in n (%). • Study design is credible as a randomized, blinded, controlled trial with objective parameters. • • Patients receiving study medicine had statistically significant symptom relief much earlier than control group. Additionally, the interventional group showed significantly lower rRT-PCR Ct values. • • Easy to reach out to the general population as study medicine constituents and easily available, it is just one day, cost effective intervention. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective A glimpse of Ayurveda -The forgotten history and principles of Indian traditional medicine Charaka Samhita of Agnivesa Pathophysiology of Covid-19 and host centric approaches in Ayurveda A critical review of concept of aging in Ayurveda Development of Ayurveda -Tradition to trend Charak Samhita with Ayurveda Deepika commentary by Chakrapani Datta Edited by Yadav ji Trikamji Acharya, Chaukhambha Prakashan Edition Sutra Sthana,1/70, Satyanarayan. Shastri Cow urine distillate as bioenhancer Therapeutic Potentials of Cow Derived Products-A Review Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis Ghee: Its properties, importance and health benefits Raw milk composition of Malian Zebu cows (Bos indicus) raised under traditional system Bio-enhancing properties of cow urine -a review Chemotherapeutic potential of cow urine: A review Physicochemical Study of Gomutra and formulation of Gomutra ARK An appraisal of medicinal properties of Shibb-e-Yamani (Alum): A review Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity COVID-19 vaccines: neutralizing antibodies and the alum advantage Clinical management protocol: COVID-19. Government of India CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials COVID-19 pandemic: A pragmatic plan for ayurveda intervention Ayurveda co-interventions have supported complete recovery in severe COVID-19 infection with a chest severity score 18/25: A case report COVID-19-affected family treated at home through integrative approach: Upbringing the concept of ayurvedic family physician for COVID cluster management single blind, randomized controlled study evaluating "AyurCoro3" as an adjuvant in the treatment of mild to moderate COVID-19 AyurCoro-3" as a prophylactic drug in frontline healthcare workers involved in treating COVID-19 patients: A pilot study Retrospective evaluation of the efficacy, safety and satisfaction of AyurCoro3: A patientreported outcomes study Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Laboratory diagnosis of COVID-19: current issues and challenges The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity Severe COVID-19 An Immunomodulatory Perspective to Alleviate the Storm Purvardha 14/15, Ambika Dutta Shastri AE/SAE recording 6 X X X X X 10Comorbid conditions X 11Concomitant medications X 12Safety follow-up 7 X X indicates procedure required on that visit day Abbreviations: AE= Adverse Event, SAE=Serious Adverse Event, rRTPCR= real time reverse transcription polymerase chain reaction. 1. Eligibility criteria were evaluated on Day-1 after informed consent procedure. For the study purpose first day is defined as randomization visit day, on which rRTPCR test was carried out. 2. Vital signs included blood pressure, pulse rate, and oxygen saturation. 3. Demographic characteristics captured included age, gender, and date of admission. Other clinical features capture include fever, cough, cold, breathlessness, body ache, diarrhoea, tastelessness, loss of smell, concomitant diseases (diabetes, hypertension, ischaemic heart disease, and renal disease), rRT-PCR values, and outcomes (discharge/death). 4. Ayurcov medication was a single day regimen, with 10 ml dose constituted medicine, three times a day. 5. Specimen samples included swabs from the nose/throat/both nose and throat/nasopharyngeal sites. Specimens collected were kept in 2-8°C ice bags and immediately transported to the laboratory. Nucleic acid extraction of SARS-CoV-2 was manually carried out in a biosafety cabinet or by automatic nucleic acid extraction system. 6. Adverse events (AE) were defined as emergence of any new symptom/s or